Quantum Genomics Enrolls First Patient in QUORUM Phase IIb Study of Firibastat in Heart Failure Patients
PARIS and NEW YORK, June 06, 2019 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical company specializing in the development of a new drug class that directly targets the brain to treat resistant hypertension …